Cargando…
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia
Autores principales: | Le, Quy, Tang, Thao, Leonti, Amanda, Castro, Sommer, McKay, Cyd Nourigat, Perkins, LaKeisha, Pardo, Laura, Kirkey, Danielle, Hylkema, Tiffany, Call, Lindsey, Manselle, Makia, Abrahams, Cristina, Bedard, Kristin, Molina, Arturo, Brodersen, Lisa Eidenshinck, Loken, Michael R., Tarlock, Katherine, Meshinchi, Soheil, Loeb, Keith R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182275/ https://www.ncbi.nlm.nih.gov/pubmed/36595452 http://dx.doi.org/10.1182/bloodadvances.2022008303 |
Ejemplares similares
-
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate
por: Tang, Thao, et al.
Publicado: (2022) -
Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022) -
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
por: Le, Quy, et al.
Publicado: (2021) -
Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001
por: Li, Xiaofan, et al.
Publicado: (2023) -
Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
por: Abrahams, Cristina L., et al.
Publicado: (2018)